San Francisco startup Structure Therapeutics is also engaged on an oral, once-everyday GLP-one drug identified as GSBR-1290—the drug surpassed Wall Avenue’s expectations in June whenever a mid-phase study showed common weight loss of around six% and it designs to begin Yet another mi